Low-Dose Aspirin for PI3K-Altered Localized Colorectal Cancer - PubMed
This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!
Clipboard, Search History, and several other advanced features are temporarily unavailable.
Skip to main page content
An official website of the United States government
Here's how you know
The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before
sharing sensitive information, make sure you’re on a federal
government site.
The site is secure.
The https:// ensures that you are connecting to the
official website and that any information you provide is encrypted
and transmitted securely.
Log in
Show account info
Close
Account
Logged in as:
username
Dashboard
Publications
Account settings
Log out
Access keys
NCBI Homepage
MyNCBI Homepage
Main Content
Main Navigation
Search:
Search
Advanced
Clipboard
User Guide
Save
Email
Send to
Clipboard
My BibliographyCollectionsCitation manager
Display options
Display options
Format
Abstract
PubMed
PMID
Save citation to file
Format:
Summary (text)
PubMed
PMID
Abstract (text)
CSV
Create file
Cancel
Email citation
Email address has not been verified. Go to
My NCBI account settings
to confirm your email and then refresh this page.
To:
Subject:
Body:
Format:
Summary
Summary (text)
Abstract
Abstract (text)
MeSH and other data
Send email
Cancel
Add to Collections
Create a new collection
Add to an existing collection
Name your collection:
Name must be less than 100 characters
Choose a collection:
Unable to load your collection due to an error
Please try again
Add
Cancel
Add to My Bibliography
My Bibliography
Unable to load your delegates due to an error
Please try again
Add
Cancel
Your saved search
Name of saved search:
Search terms:
Test search terms
Would you like email updates of new search results?
Saved Search Alert Radio Buttons
Yes
No
Email:
(change)
Frequency:
Monthly
Weekly
Daily
Which day?
The first Sunday
The first Monday
The first Tuesday
The first Wednesday
The first Thursday
The first Friday
The first Saturday
The first day
The first weekday
Which day?
Sunday
Monday
Tuesday
Wednesday
Thursday
Friday
Saturday
Report format:
Summary
Summary (text)
Abstract
Abstract (text)
PubMed
Send at most:
1 item
5 items
10 items
20 items
50 items
100 items
200 items
Send even when there aren't any new results
Optional text in email:
Save
Cancel
Create a file for external citation management software
Create file
Cancel
Your RSS Feed
Name of RSS Feed:
Number of items displayed:
5
10
15
20
50
100
Create RSS
Cancel
RSS Link
Copy
Full text links
Atypon
Full text links
ActionsCiteCollectionsAdd to CollectionsCreate a new collectionAdd to an existing collection
Name your collection:
Name must be less than 100 characters
Choose a collection:
Unable to load your collection due to an errorPlease try again
Add
Cancel
PermalinkPermalinkCopyDisplay options
Display options
Format
AbstractPubMedPMID
Page navigation
Title & authors
Abstract
Publication types
MeSH terms
Substances
Associated data
Grants and funding
LinkOut - more resources
Title & authors
Abstract
Publication types
MeSH terms
Substances
Associated data
Grants and funding
LinkOut - more resources
Clinical Trial
N Engl J Med
Actions
Search in PubMed
Search in NLM Catalog
Add to Search
. 2025 Sep 18;393(11):1051-1064.
doi: 10.1056/NEJMoa2504650.
Low-Dose Aspirin for PI3K-Altered Localized Colorectal Cancer
Anna Martling
1
2
, Ida Hed Myrberg
3
, Mef Nilbert
4
, Henrik Grönberg
5
, Fredrik Granath
3
, Martin Eklund
5
, Tom Öresland
6
7
, Lene H Iversen
8
, Carola Haapamäki
9
, Martin Janson
10
, Karin Westberg
1
11
, Josefin Segelman
1
12
, Urban Ersson
13
, Mattias Prytz
14
15
, Eva Angenete
15
16
, Rebecka Bergström
5
, Markus Mayrhofer
5
17
, Bengt Glimelius
18
, Johan Lindberg
19
; ALASCCA Study Group
Collaborators,
Affiliations
Expand
Collaborators
ALASCCA Study Group:
Anna Martling, Bengt Glimelius, Henrik Grönberg, Mef Nilbert, Johan Lindberg, Rebecka Bergström, Markus Mayrhofer, Venkatesh Chellappa, Ida Hed Myrberg, Sandra Eloranta, Annika Dominicus, Fredrik Granath, Madelene Ahlberg, Sabine Süllow Barin, Eva Angenete, Zunash Malik, Per Loftås, Malin Olsson, Karin Westberg, Josefin Karlsson, Josefin Segelman, Dubravka Jaksic, Frida Lédel, Richard Bernhoff, Martin Janson, Bastan Jansson Grönwald, Urban Ersson, Berith Wennström, Mattias Prytz, Malin Samuelsson, Marcel Sadeghi, Anna Leppänen, Ingvar Syk, Caroline Nilsson, Petra Flygare, Christine Näslund, Markku Haapamäki, Agneta Karhu, Christoffer Odensten, Pia Näsvall, Staffan Haapaniemi, Anna Benckert, Helena Laurell, Morgan Nordén, Åsa Olofsson, Helgi Birgisson, Annika Lidén, Kenneth Smed, Malin Engdahl, Niklas Zar, Therése Karlsson, Mattias Söderholm, Monica Olsson, Peter Matthiessen, Lena Hansson, Kamilla Persson, Karin Nyqvist, Tom Øresland, Marianne Aarstad Merok, Merete Helgeland, William Lossius, Hans Wasmuth, Torhild Veen, Ramesh Khajavi-Larsen, Trond Dehli, Kristin Woll, Lene H Iversen, Kirsten Haupt, Susanne Haas, Katrine J Emmertsen, Annette Boesen Bräuner, Lea Bundgård, Carola Haapamäki, Ilona Keränen, Selja Koskensalo, Taru Lehtonen, Anders Ekbom, Rolf Hultcrantz, Johan Permert
Affiliations
1 Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm.
2 Theme Cancer, Department of Pelvic Cancer, Karolinska University Hospital, Stockholm.
3 Clinical Epidemiology Division, Department of Medicine Solna, Karolinska Institutet, Stockholm.
4 Institute of Clinical Sciences, Lund University and Skane University Hospital Cancer Center, Lund, Sweden.
5 Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm.
6 Department of Gastrointestinal Surgery, Akershus University Hospital, Oslo.
7 Clinic for Surgical Sciences, University of Oslo, Oslo.
8 Department of Surgery, Aarhus University Hospital, Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.
9 Department of Gastroenterologic Surgery, Helsinki University Hospital and University of Helsinki, Helsinki.
10 Department of Clinical Science and Education, Stockholm South General Hospital, Stockholm.
11 Danderyds Hospital, Department of Surgery, Stockholm.
12 Ersta Hospital, Department of Surgery, Stockholm.
13 Skaraborg Hospital, Skövde, Sweden.
14 Department of Surgery, Region Västra Götaland, NU Hospital group, Trollhättan, Sweden.
15 Department of Surgery, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
16 Department of Surgery, Sahlgrenska University Hospital-Östra, Region Västra Götaland, Gothenburg, Sweden.
17 National Bioinformatics Infrastructure Sweden, Science for Life Laboratory, Department of Cell and Molecular Biology, Uppsala University, Uppsala, Sweden.
18 Department of Immunology, Genetics, and Pathology, Uppsala University, Uppsala, Sweden.
19 Department of Medical Epidemiology and Biostatistics, Science for Life Laboratory, Karolinska Institutet, Stockholm.
PMID:
40961426
DOI:
10.1056/NEJMoa2504650
Item in Clipboard
Clinical Trial
Low-Dose Aspirin for PI3K-Altered Localized Colorectal Cancer
Anna Martling et al.
N Engl J Med.
2025.
Show details
Display options
Display options
Format
Abstract
PubMed
PMID
N Engl J Med
Actions
Search in PubMed
Search in NLM Catalog
Add to Search
. 2025 Sep 18;393(11):1051-1064.
doi: 10.1056/NEJMoa2504650.
Authors
Anna Martling
1
2
, Ida Hed Myrberg
3
, Mef Nilbert
4
, Henrik Grönberg
5
, Fredrik Granath
3
, Martin Eklund
5
, Tom Öresland
6
7
, Lene H Iversen
8
, Carola Haapamäki
9
, Martin Janson
10
, Karin Westberg
1
11
, Josefin Segelman
1
12
, Urban Ersson
13
, Mattias Prytz
14
15
, Eva Angenete
15
16
, Rebecka Bergström
5
, Markus Mayrhofer
5
17
, Bengt Glimelius
18
, Johan Lindberg
19
; ALASCCA Study Group
Collaborators
ALASCCA Study Group:
Anna Martling, Bengt Glimelius, Henrik Grönberg, Mef Nilbert, Johan Lindberg, Rebecka Bergström, Markus Mayrhofer, Venkatesh Chellappa, Ida Hed Myrberg, Sandra Eloranta, Annika Dominicus, Fredrik Granath, Madelene Ahlberg, Sabine Süllow Barin, Eva Angenete, Zunash Malik, Per Loftås, Malin Olsson, Karin Westberg, Josefin Karlsson, Josefin Segelman, Dubravka Jaksic, Frida Lédel, Richard Bernhoff, Martin Janson, Bastan Jansson Grönwald, Urban Ersson, Berith Wennström, Mattias Prytz, Malin Samuelsson, Marcel Sadeghi, Anna Leppänen, Ingvar Syk, Caroline Nilsson, Petra Flygare, Christine Näslund, Markku Haapamäki, Agneta Karhu, Christoffer Odensten, Pia Näsvall, Staffan Haapaniemi, Anna Benckert, Helena Laurell, Morgan Nordén, Åsa Olofsson, Helgi Birgisson, Annika Lidén, Kenneth Smed, Malin Engdahl, Niklas Zar, Therése Karlsson, Mattias Söderholm, Monica Olsson, Peter Matthiessen, Lena Hansson, Kamilla Persson, Karin Nyqvist, Tom Øresland, Marianne Aarstad Merok, Merete Helgeland, William Lossius, Hans Wasmuth, Torhild Veen, Ramesh Khajavi-Larsen, Trond Dehli, Kristin Woll, Lene H Iversen, Kirsten Haupt, Susanne Haas, Katrine J Emmertsen, Annette Boesen Bräuner, Lea Bundgård, Carola Haapamäki, Ilona Keränen, Selja Koskensalo, Taru Lehtonen, Anders Ekbom, Rolf Hultcrantz, Johan Permert
Affiliations
1 Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm.
2 Theme Cancer, Department of Pelvic Cancer, Karolinska University Hospital, Stockholm.
3 Clinical Epidemiology Division, Department of Medicine Solna, Karolinska Institutet, Stockholm.
4 Institute of Clinical Sciences, Lund University and Skane University Hospital Cancer Center, Lund, Sweden.
5 Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm.
6 Department of Gastrointestinal Surgery, Akershus University Hospital, Oslo.
7 Clinic for Surgical Sciences, University of Oslo, Oslo.
8 Department of Surgery, Aarhus University Hospital, Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.
9 Department of Gastroenterologic Surgery, Helsinki University Hospital and University of Helsinki, Helsinki.
10 Department of Clinical Science and Education, Stockholm South General Hospital, Stockholm.
11 Danderyds Hospital, Department of Surgery, Stockholm.
12 Ersta Hospital, Department of Surgery, Stockholm.
13 Skaraborg Hospital, Skövde, Sweden.
14 Department of Surgery, Region Västra Götaland, NU Hospital group, Trollhättan, Sweden.
15 Department of Surgery, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
16 Department of Surgery, Sahlgrenska University Hospital-Östra, Region Västra Götaland, Gothenburg, Sweden.
17 National Bioinformatics Infrastructure Sweden, Science for Life Laboratory, Department of Cell and Molecular Biology, Uppsala University, Uppsala, Sweden.
18 Department of Immunology, Genetics, and Pathology, Uppsala University, Uppsala, Sweden.
19 Department of Medical Epidemiology and Biostatistics, Science for Life Laboratory, Karolinska Institutet, Stockholm.
PMID:
40961426
DOI:
10.1056/NEJMoa2504650
Item in Clipboard
Full text links
CiteDisplay options
Display options
Format
AbstractPubMedPMID
Abstract
Background:
Aspirin reduces the incidence of colorectal adenoma and colorectal cancer among high-risk persons. Observational studies suggest that aspirin may also improve disease-free survival after diagnosis, particularly among patients with tumors harboring somatic PIK3CA mutations. However, data from randomized trials are lacking.
Methods:
We conducted a double-blind, randomized, placebo-controlled trial involving patients with stage I, II, or III rectal cancer or stage II or III colon cancer with somatic alterations in PI3K pathway genes. The patients were assigned in a 1:1 ratio to receive 160 mg of aspirin or matched placebo once daily for 3 years. Patients with prespecified PIK3CA hotspot mutations in exon 9 or 20 (group A alterations) and those with other moderate- or high-impact somatic variants in PIK3CA, PIK3R1, or PTEN (group B alterations) were eligible for randomization. The primary end point was colorectal cancer recurrence, assessed in a time-to-event analysis, in patients with group A alterations. Secondary end points included colorectal cancer recurrence in patients with group B alterations, disease-free survival, and safety.
Results:
Alterations in PI3K pathway genes were detected in 1103 of 2980 patients (37.0%) with complete genomic data. Of 515 patients with group A alterations and 588 patients with group B alterations, 314 and 312, respectively, were assigned to receive aspirin or placebo. The estimated 3-year cumulative incidence of recurrence was 7.7% with aspirin and 14.1% with placebo (hazard ratio, 0.49; 95% confidence interval [CI], 0.24 to 0.98; P = 0.04) among patients with group A alterations and 7.7% and 16.8%, respectively (hazard ratio, 0.42; 95% CI, 0.21 to 0.83), among those with group B alterations. The estimated 3-year disease-free survival was 88.5% with aspirin and 81.4% with placebo (hazard ratio, 0.61; 95% CI, 0.34 to 1.08) among patients with group A alterations and 89.1% and 78.7%, respectively (hazard ratio, 0.51; 95% CI, 0.29 to 0.88), among those with group B alterations. Severe adverse events occurred in 16.8% of aspirin recipients and 11.6% of placebo recipients.
Conclusions:
Aspirin led to a significantly lower incidence of colorectal cancer recurrence than placebo among patients with PIK3CA hotspot mutations in exon 9 or 20 and appeared to have a similar benefit among those with other somatic alterations in PI3K pathway genes. (Funded by the Swedish Research Council and others; ALASCCA ClinicalTrials.gov number, NCT02647099; EudraCT number, 2015-004240-19.).
Copyright © 2025 Massachusetts Medical Society.
PubMed Disclaimer
Publication types
Clinical Trial, Phase III
Actions
Search in PubMed
Search in MeSH
Add to Search
Multicenter Study
Actions
Search in PubMed
Search in MeSH
Add to Search
Randomized Controlled Trial
Actions
Search in PubMed
Search in MeSH
Add to Search
MeSH terms
Adult
Actions
Search in PubMed
Search in MeSH
Add to Search
Aged
Actions
Search in PubMed
Search in MeSH
Add to Search
Aged, 80 and over
Actions
Search in PubMed
Search in MeSH
Add to Search
Aspirin* / administration & dosage
Actions
Search in PubMed
Search in MeSH
Add to Search
Aspirin* / adverse effects
Actions
Search in PubMed
Search in MeSH
Add to Search
Biomarkers, Tumor* / genetics
Actions
Search in PubMed
Search in MeSH
Add to Search
Class I Phosphatidylinositol 3-Kinases* / genetics
Actions
Search in PubMed
Search in MeSH
Add to Search
Class Ia Phosphatidylinositol 3-Kinase / genetics
Actions
Search in PubMed
Search in MeSH
Add to Search
Colonic Neoplasms* / drug therapy
Actions
Search in PubMed
Search in MeSH
Add to Search
Colonic Neoplasms* / genetics
Actions
Search in PubMed
Search in MeSH
Add to Search
Colonic Neoplasms* / mortality
Actions
Search in PubMed
Search in MeSH
Add to Search
Colonic Neoplasms* / pathology
Actions
Search in PubMed
Search in MeSH
Add to Search
Disease-Free Survival
Actions
Search in PubMed
Search in MeSH
Add to Search
Dose-Response Relationship, Drug
Actions
Search in PubMed
Search in MeSH
Add to Search
Double-Blind Method
Actions
Search in PubMed
Search in MeSH
Add to Search
Female
Actions
Search in PubMed
Search in MeSH
Add to Search
Humans
Actions
Search in PubMed
Search in MeSH
Add to Search
Incidence
Actions
Search in PubMed
Search in MeSH
Add to Search
Male
Actions
Search in PubMed
Search in MeSH
Add to Search
Middle Aged
Actions
Search in PubMed
Search in MeSH
Add to Search
Mutation
Actions
Search in PubMed
Search in MeSH
Add to Search
Neoplasm Recurrence, Local / epidemiology
Actions
Search in PubMed
Search in MeSH
Add to Search
Neoplasm Recurrence, Local / genetics
Actions
Search in PubMed
Search in MeSH
Add to Search
Neoplasm Recurrence, Local / prevention & control
Actions
Search in PubMed
Search in MeSH
Add to Search
Neoplasm Staging
Actions
Search in PubMed
Search in MeSH
Add to Search
PTEN Phosphohydrolase / genetics
Actions
Search in PubMed
Search in MeSH
Add to Search
Phosphatidylinositol 3-Kinases* / genetics
Actions
Search in PubMed
Search in MeSH
Add to Search
Rectal Neoplasms* / drug therapy
Actions
Search in PubMed
Search in MeSH
Add to Search
Rectal Neoplasms* / genetics
Actions
Search in PubMed
Search in MeSH
Add to Search
Rectal Neoplasms* / mortality
Actions
Search in PubMed
Search in MeSH
Add to Search
Rectal Neoplasms* / pathology
Actions
Search in PubMed
Search in MeSH
Add to Search
Substances
Aspirin
Actions
Search in PubMed
Search in MeSH
Add to Search
Class I Phosphatidylinositol 3-Kinases
Actions
Search in PubMed
Search in MeSH
Add to Search
Phosphatidylinositol 3-Kinases
Actions
Search in PubMed
Search in MeSH
Add to Search
PIK3CA protein, human
Actions
Search in PubMed
Search in MeSH
Add to Search
PTEN Phosphohydrolase
Actions
Search in PubMed
Search in MeSH
Add to Search
PTEN protein, human
Actions
Search in PubMed
Search in MeSH
Add to Search
Biomarkers, Tumor
Actions
Search in PubMed
Search in MeSH
Add to Search
PIK3R1 protein, human
Actions
Search in PubMed
Search in MeSH
Add to Search
Class Ia Phosphatidylinositol 3-Kinase
Actions
Search in PubMed
Search in MeSH
Add to Search
Associated data
ClinicalTrials.gov/NCT02647099
Actions
Search in PubMed
Search in ClinicalTrials.gov
EudraCT/2015-004240-19
Grants and funding
2014-38551-117568-77/Vetenskapsrådet
LinkOut - more resources
Full Text Sources
Atypon
Research Materials
NCI CPTC Antibody Characterization Program
Miscellaneous
NCI CPTAC Assay Portal
Full text links
[x]
Atypon
[x]
Cite
Copy
Download .nbib
.nbib
Format:
AMA
APA
MLA
NLM
Send To
Clipboard
Email
Save
My Bibliography
Collections
Citation Manager
[x]
NCBI Literature Resources
MeSH
PMC
Bookshelf
Disclaimer
The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). Unauthorized use of these marks is strictly prohibited.
Follow NCBI
Twitter
Facebook
LinkedIn
GitHub
Connect with NLM
Twitter
SM-Facebook
SM-Youtube
National Library of Medicine
8600 Rockville Pike
Bethesda, MD 20894
Web Policies
FOIA
HHS Vulnerability Disclosure
Help
Accessibility
Careers
NLM
NIH
HHS
USA.gov